University of Queensland researchers who mapped cancer cell "neighborhoods" in the most common type of lung cancer have found ...

Imdelltra significantly improves survival in SCLC patients post-platinum chemotherapy, meeting primary endpoints in the DeLLphi-304 trial. As a BiTE immunotherapy, Imdelltra enhances T cell-cancer ...

This is a "landmark study" for cancer immunotherapy and circadian medicine, researcher say ...

Imdelltra demonstrated superior overall survival and progression-free survival compared to standard chemotherapy in ES-SCLC patients post-platinum-based treatment. The DeLLphi-304 trial showed a ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...